DoMore Diagnostics and the EIC Accelerator: AI to Guide Chemotherapy

DoMore Diagnostics, based in Oslo, makes Histotype Px Colorectal, a deep-learning test that reads ordinary haematoxylin and eosin-stained tumour slides to predict how patients with stage II and III colorectal cancer will fare, helping doctors decide who needs chemotherapy after surgery. The EIC Accelerator granted €2,500,000 towards a total cost of €5,326,968 for the Histotype Px project, which runs from June 2024 to May 2027, according to CORDIS. The project report calls it "the world's first CE-marked AI-based digital biomarker" for treatment decisions in these cancers.

By May 2025, the report says, DoMore had completed analyses and publications validating the test in hospitals in Europe, the US and Japan, alone and combined with liquid biopsy, and developed a secure cloud portal, with a first submission for inclusion in clinical guidelines expected in 2025, according to CORDIS. Data from a Dutch cohort were presented orally at ESMO in 2025, and results on predicting chemotherapy benefit were presented at ASCO GI in January 2026, according to DoMore. DoMore's 2025 accounts show revenue of NOK 185,444 and nine employees, according to the Brønnøysund Register Centre. No guideline inclusion has been announced.

Where DoMore Stands Now

In August 2026 DoMore announced a collaboration with the IFOM cancer institute in Milan to validate Histotype Px combined with circulating tumour DNA, and earlier collaborations with the French FFCD group and Erasmus MC. The Research Council of Norway awarded it NOK 16 million, under its 2024 call, for a project with Oslo University Hospital to combine the test with ctDNA and develop a new biomarker for residual disease, according to DoMore. It has been granted patents in the US, Japan and Korea.

The Technology: Reading Slides Pathologists Already Make

After surgery for stage II or III colon cancer, doctors must decide whether chemotherapy is worth its side effects. DoMore's partner IFOM says current criteria leave many patients undertreated or overtreated. Histotype Px uses deep learning on the standard stained slides every hospital already produces, so no extra tissue or lab test is needed. The EIC project also aims to show it predicts who benefits from chemotherapy, not just who is at risk.

What the EIC Award Promised, and What the Record Shows

The project runs until May 2027, so it is too early to judge it. It has produced wider clinical validation and conference data. The step that would drive sales, inclusion in treatment guidelines, was expected to be submitted in 2025, and no outcome has been announced.

1. External clinical validationDeliveredEurope, US, Japan.
2. Secure cloud servicePortal builtProject report.
3. Guideline inclusionUnverifiedNot announced.
4. Commercial uptakeMinimalNOK 185k, 2025.

The Money

The EU grant covers 47% of the €5.3 million project. DoMore ended 2025 with equity of NOK 21.8 million and reported an operating loss of NOK 303,107. The award was blended finance; no EIC Fund investment has been announced.

What Cannot Be Checked

Why Europe Should Care

A test that spares low-risk patients unnecessary chemotherapy, and flags high-risk patients who need it, would improve care and save money. DoMore's approach needs no new hardware in hospitals. It will only change practice if guidelines adopt it.

The Verdict

DoMore Diagnostics and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.